研究发现，用于治疗感染性腹泻的抗生素可能是一种有效的炎症性肠病的药物

英国伯明翰大学的研究人员表明，一种称为万古霉素的抗生素也可能有效地治疗具有特定类型的人

An antibiotic used to treat infective diarrhoea may be an effective drug for a type of inflammatory bowel disease, according to a new study.

一项新研究显示，一种用于治疗感染性腹泻的抗生素可能是一种有效的炎症性肠病的有效药物。

Researchers from the University of Birmingham showed that an antibiotic called vancomycin may also be effective in treating people who have a specific type of inflammatory bowel disease (IBD), which develops due to an incurable autoimmune liver disease called primary sclerosing cholangitis (PSC).

伯明翰大学的研究人员表明，一种称为万古霉素的抗生素也可能有效地治疗患有特定类型的炎症性肠病（IBD）的人，该抗生素由于可治疗的自身免疫性肝脏疾病而发展，该疾病被称为原发性硬化性胆管炎（PSC）。

Notably, four in five patients who participated in the study achieved remission after taking the drug as part of a clinical trial published in the Journal of Crohn's and Colitis.

值得注意的是，参加该研究的五分之四的患者在将药物作为克罗恩杂志和结肠炎杂志发表的临床试验的一部分后获得了缓解。

The study is significant, as several participants with this disease had not responded to other IBD treatments.

这项研究很重要，因为该疾病的一些参与者未对其他IBD治疗做出反应。

Moreover, IBD and PSC are closely correlated, with most individuals who have PSC developing IBD, and up to 14 per cent of patients with IBD also developing PSC.

此外，IBD和PSC密切相关，大多数患有PSC开发IBD的人，而IBD患者中最多也有14％的患者也在发展PSC。

Together, the condition raised the need for colon surgery and or developing colon or liver cancer, which would them need a liver transplant. It also raises the overall risk of death.

这种情况共同提高了结肠手术和或发展结肠或肝癌的需求，它们需要进行肝移植。它还增加了死亡的总体风险。

"Our findings suggest that vancomycin could offer a new therapeutic option for patients with this challenging combination of IBD and autoimmune liver disease," said Dr. Mohammed Nabil Quraishi from the University of Birmingham.

伯明翰大学的Mohammed Nabil Quraishi博士说：“我们的发现表明，万古霉素可以为IBD和自身免疫性肝病的这种具有挑战性的患者提供一种新的治疗选择。”

During the trial, participants were treated with oral antibiotics for four weeks. About 80 per cent of patients achieved clinical remission after the treatment.

在试验期间，将参与者用口服抗生素治疗四个星期。治疗后，约有80％的患者在临床缓解中得到了缓解。

They also showed a significant decrease in inflammatory markers, and 100 per cent showed mucosal healing.

它们还显示出炎症标记的显着降低，100％显示粘膜愈合。

However, when the treatment was stopped after 8 weeks, the symptoms returned.

但是，当治疗在8周后停止治疗时，症状恢复了。

Vancomycin was also shown to induce changes in certain bile acids, which are now being further investigated to develop and refine treatments for IBD-associated PSC.

Vancomycin还显示出诱导某些胆汁酸的变化，现在正在进一步研究这些胆汁酸，以开发和完善与IBD相关的PSC的处理。

Although the results are preliminary, they provide a strong foundation for further research, said the team.

该团队说，尽管结果是初步的，但它们为进一步的研究提供了坚实的基础。